ERYTHROMYCIN STEARATE

Search structure


Trade Names:	BRISTAMYCIN ERYPAR ERYTHROCIN STEARATE ERYTHROMYCIN STEARATE ETHRIL 250 ETHRIL 500 PFIZER-E WYAMYCIN S
Synonyms:	Abboticine Bristamycin Erypar Erythrocin Erythrocin 500 Erythrocin acne pack Erythrocin stearate Erythromycini stearas Erythromycin stearate Ethril 250 Ethril 500 NSC-756747 Pfizer-e Sk-erythromycin Wyamycin s
Status:	Approved (1964)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	LXW024X05M
Parent Compound:	ERYTHROMYCIN

Structure


InChI Key	YAVZHCFFUATPRK-YZPBMOCRSA-N
Smile	CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
InChI	InChI=1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C55H103NO15
Molecular Weight	1018.42
AlogP	1.79
Hydrogen Bond Acceptor	14.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	7.0
Polar Surface Area	193.91
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	51.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial 70S ribosome inhibitor	PubMed FDA

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	100

Metabolites

visNetwork

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Pregnancy, puerperium and perinatal conditions	18.56
Injury, poisoning and procedural complications	9.22
Respiratory, thoracic and mediastinal disorders	7.54
Nervous system disorders	7.31
Gastrointestinal disorders	7.19
General disorders and administration site conditions	6.95
Vascular disorders	6.23
Investigations	5.39
Immune system disorders	5.27
Cardiac disorders	4.55
Skin and subcutaneous tissue disorders	4.43
Ear and labyrinth disorders	3.23
Psychiatric disorders	2.63
Hepatobiliary disorders	2.16

Cross References

Resources	Reference
ChEBI	34742
ChEMBL	CHEMBL1200510
EPA CompTox	DTXSID0020571
FDA SRS	LXW024X05M
PubChem	12559
SureChEMBL	SCHEMBL536998

CONTENTS